Usted buscó: certolizumabpegol (Croata - Inglés)

cimzia certolizumabpegol
cimzia certolizumab pegol

djelatna tvar je certolizumabpegol.
the active substance is certolizumab pegol.

ispitivanja karcinogenosti za certolizumabpegol nisu provedena.
carcinogenicity studies have not been performed with certolizumab pegol.

certolizumabpegol ne reagira križno s tnf-om glodavaca.
certolizumab pegol does not cross-react with rodent tnf.

cimzia 200 mg otopina za injekciji u napunjenoj brizgalici certolizumabpegol
cimzia 200 mg solution for injection in pre-filled pen certolizumab pegol

cimzia je otopina za ubrizgavanje koja sadrži djelatnu tvar certolizumabpegol.
cimzia is a solution for injection that contains the active substance certolizumab pegol.

prisutnost protutijela na certolizumabpegol uzrokovala je otprilike trostruko povećanje klirensa.
the presence of antibodies to certolizumab pegol resulted in an approximately three-fold increase in clearance.

inhibiranjem tnf-alfe, certolizumabpegol smanjuje upalu i druge simptome bolesti.
by blocking tnf-alpha, certolizumab pegol reduces the inflammation and other symptoms of the diseases.

certolizumabpegol dizajniran je za vezivanje na posrednički protein u tijelu faktor nekroze tumora alfa (tnf-alfa).
certolizumab pegol has been designed to attach to a messenger protein in the body called tumour necrosis factor alpha (tnf-alpha).

djelatna tvar lijeka cimzia, certolizumabpegol, je imunosupresiv, lijek koji smanjuje aktivnost imunosnog sustava (prirodne obrane tijela).
the active substance in cimzia, certolizumab pegol, is an immunosuppressant medicine, a medicine that reduces the activity of the immune system (the body’s natural defences).

certolizumabpegol je rekombinantni fab fragment humaniziranog protutijela protiv faktora nekroze tumora alfa (tnfα) eksprimiran u escherichiji coli i konjugiran s polietilenglikolom (peg).
certolizumab pegol is a recombinant, humanised antibody fab' fragment against tumour necrosis factor alpha (tnfα) expressed in escherichia coli and conjugated to polyethylene glycol (peg).

reaktivacija hepatitisa b pojavila se u bolesnika kroničnih nositelja tog virusa (tj. pozitivni na površinski antigen) koji su primali tnf-antagoniste, uključujući certolizumabpegol.
reactivation of hepatitis b has occurred in patients receiving a tnf-antagonist including certolizumab pegol, who are chronic carriers of this virus (i.e., surface antigen positive).